PNC Financial Services Group Inc. Has $54.95 Million Position in Zoetis Inc. (NYSE:ZTS)

PNC Financial Services Group Inc. decreased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 281,230 shares of the company's stock after selling 12,064 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.06% of Zoetis worth $54,947,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Axxcess Wealth Management LLC grew its position in Zoetis by 17.4% in the 1st quarter. Axxcess Wealth Management LLC now owns 9,826 shares of the company's stock worth $1,663,000 after purchasing an additional 1,458 shares during the last quarter. Advisors Asset Management Inc. raised its stake in shares of Zoetis by 4.4% in the first quarter. Advisors Asset Management Inc. now owns 16,168 shares of the company's stock valued at $2,736,000 after acquiring an additional 678 shares during the last quarter. Toronto Dominion Bank boosted its stake in Zoetis by 17.5% in the first quarter. Toronto Dominion Bank now owns 308,667 shares of the company's stock worth $52,230,000 after purchasing an additional 46,001 shares in the last quarter. Capital Research Global Investors grew its holdings in Zoetis by 2.3% during the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company's stock worth $685,416,000 after acquiring an additional 90,330 shares during the last quarter. Finally, Westwood Holdings Group Inc. increased its holdings in shares of Zoetis by 4.1% in the first quarter. Westwood Holdings Group Inc. now owns 163,965 shares of the company's stock valued at $27,745,000 after purchasing an additional 6,494 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.1 %

Shares of NYSE:ZTS opened at $175.67 on Thursday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The business's 50 day simple moving average is $186.18 and its 200 day simple moving average is $180.47. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market capitalization of $79.26 billion, a P/E ratio of 33.02, a P/E/G ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the company posted $1.36 EPS. The company's revenue for the quarter was up 11.6% compared to the same quarter last year. On average, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis's dividend payout ratio is currently 32.52%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ZTS shares. Argus upgraded shares of Zoetis to a "strong-buy" rating in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a report on Monday, August 12th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an "overweight" rating in a research report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.